Filter
66
Text search:
DNDi
-
Drugs
for
neglected
diseases
initiative
Featured
7
4
Language
Document type
31
8
6
5
5
5
3
2
1
Countries
9
7
4
2
2
2
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
13
8
2
1
Toolboxes
49
2
2
1
1
1
1
1
1
Glob Heart . 2020 Oct 13;15(1):69. doi: 10.5334/gh.891.
Lessons from the STEP-TB Project.
Accessed November 2017.
Over 6 million people worldwide are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease
(CD). T. cruzi is transmitted by triatomine insects, congenitally, through uncontrolled blood donations and organ transplants,
and via consumption of food or drink contaminated by triatomi
...
Technology landscape
This document focuses on making recommendations for the diagnosis and treatment of Chagas disease, an infection caused by Trypanosoma cruzi, the protozoan agent of a systemic parasitic disease. Methodology: These clinical practice guidelines were pr
...
2nd edition. These guidelines include several notable changes from the first edition. For cutaneous leishmaniasis, ketoconazole has been removed from the list of treatment options; the number of Leishmania species
...
Not long ago, on the occasion of the 100th anniversary of the discovery of Chagas disease, several campaigns denounced the scant progress has been made in diffrent spheres- medical, scientific and politcal- but major challanges still remain. This is an appropriate time to celebrate what has been ach
...
Rreport of a WHO Consultative Meeting Kolkata India 2012
Over 6 million people worldwide are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease. Endemic in 21 Latin American countries, the disease can be transmitted by vector insects called triatomines — also known as “kissing bugs” —, foods or beverages contaminated with th
...
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has impr
...
The growing challenges for people in low and middle-income countries to access new medicines.
Analysis 58
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the vari
...
As countries presented their epidemiological and programmatic situations, and WHO summarized the global status of HAT, the central message was one of satisfaction with the remarkable progress towards elimination. A historically low number of cases was reported, despite maintaining high levels of act
...
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr
...
A Mini Review of Antiparasitic Agents explored between 2010-2021. Frontiers in Chemistry 9:771143
The Lancet Volume 5, Issue 10100972October 2024 Chagas Disease Serie 3
The Lancet Microbe Series Chagas Disease 2 Volume 5, Issue 10100946 October 2024
Rev Panam Salud Publica 2023;47:e141. https://doi.org/10.26633/RPSP.2023.141
